Rifaximin

Rifaximin is an orally administered antibiotic produced by chemical modification of rifamycin, the natural product family that also gives rise to rifampicin. Its defining pharmacological property is extremely low systemic absorption, so that after a tablet is swallowed the drug stays almost entirely within the gut, reaching very high concentrations in the intestinal contents and stool while blood levels remain minimal ^[2]. This gut-restricted behavior underlies both its therapeutic profile and its favorable tolerability, since little of the compound circulates through the rest of the body ^[1].

The compound was first approved in Italy in the late 1980s and has since been registered in many countries for a range of gastrointestinal conditions. In the United States it is a prescription-only medicine sold as Xifaxan, with regulatory clearances that expanded over time to cover travelers' diarrhea, reduction in the recurrence of overt hepatic encephalopathy, and irritable bowel syndrome with diarrhea ^[1]. It is also known under names such as Normix and Zaxine in other markets.

In liver disease, rifaximin is given to lower the burden of ammonia-forming intestinal bacteria and thereby reduce episodes of hepatic encephalopathy, a use supported by randomized trials and meta-analyses that show fewer recurrences and hospitalizations compared with placebo ^[3]. Research has extended to other complications of cirrhosis, including trials examining whether the drug can prevent bacterial infection in advanced disease, although results here have been mixed ^[4]. In functional bowel disorders it is used as a short course for diarrhea-predominant irritable bowel syndrome, where it can improve bloating, abdominal discomfort, and stool consistency in a subset of patients ^[1].

Rifaximin is supplied as oral tablets. Because it exists in several crystalline forms that differ in solubility, the specific polymorph used in a product can influence how much of the drug remains in the gut, a factor relevant to how it is formulated ^[2].

Rifaximin is prescription only and, because so little is absorbed, it is remarkably well tolerated. Common effects are mild; nausea, bloating, gas, abdominal discomfort and headache, and in people treated for hepatic encephalopathy some ankle swelling and dizziness. Serious problems are uncommon, though as with any antibiotic there is a small risk of Clostridioides difficile infection. In severe liver impairment a bit more of the drug can reach the blood, so caution is used there. It has few drug interactions thanks to its low absorption, but strong P glycoprotein inhibitors such as cyclosporine can raise its systemic levels.

Rifaximin is barely absorbed, which is rather the point of it, and that keeps its interaction profile small. What little absorption occurs depends on P-glycoprotein and OATP transporters, and blocking them changes the picture dramatically: a single dose of cyclosporine raised rifaximin Cmax about 83-fold and AUC about 124-fold in healthy subjects. Absolute concentrations stay low, but that scale of increase carries more weight in people with impaired liver function, whose baseline absorption is already higher.

Unlike rifampin, rifaximin does not act as a meaningful systemic enzyme inducer at usual doses. A three-day course left the pharmacokinetics of ethinyl estradiol and norgestimate unchanged in healthy women, so the contraceptive failure risk that rifampin carries does not transfer to rifaximin.

Post-marketing reports describe INR changes, in both directions, in patients on warfarin who started rifaximin. The mechanism is unsettled, with in vitro CYP3A4 induction and altered gut flora both proposed, and coagulation monitoring is how the uncertainty is handled.

Checking a whole stack? Run it through interactions + stacks.

Rifaximin was developed by the Italian pharmaceutical company Alfa Wassermann, whose chemists synthesized it in 1982 as a semisynthetic derivative of rifamycin SV. The defining modification was the addition of a pyridoimidazole ring, a change that rendered the molecule almost entirely non-absorbable so that it would concentrate within the gut rather than enter the bloodstream. It was first approved in Italy and marketed there as Normix in 1987, initially for intestinal infections and related gastrointestinal conditions.

In the United States the compound was advanced by Salix Pharmaceuticals under the brand name Xifaxan, gaining FDA approval in 2004 for travelers' diarrhea caused by noninvasive Escherichia coli. Its indications later expanded to the reduction of recurrent hepatic encephalopathy in 2010 and to diarrhea-predominant irritable bowel syndrome in 2015, milestones supported by large controlled trials.

Rifaximin is widely regarded as a distinctive antibiotic because it delivers strong local antibacterial action in the intestine while leaving systemic drug levels negligible, a profile that clinicians value for its favorable tolerability. In hepatic encephalopathy it has become a mainstay for preventing relapse, and many patients experience meaningfully fewer hospitalizations when it is added to standard care.

Its approval for irritable bowel syndrome broadened interest in the gut microbiome as a driver of functional bowel symptoms, and the short treatment courses it allows are appreciated by both patients and physicians. Researchers continue to study effects that appear to reach beyond simple bacterial killing, including shifts in microbial activity and signaling through the pregnane X receptor. It is not a cure for these chronic conditions, and symptoms can return, but its combination of efficacy and a clean safety record has earned it a durable place in gastroenterology.